Drug profile
The FDA adverse-event record for Trilostane
15,369 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Trilostane. See the species affected, top reactions, and outcomes below.
- 15,369
- adverse-event reports
- 10.8%
- death-coded share
- Dog
- most-reported species
- 2,678
- Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Trilostane Adverse Event Insights
15,369 reports name Trilostane; 1,661 recorded a death outcome (10.8% of reported events, not a population-level mortality rate). Active ingredient: Trilostane. Administration routes: Oral, Unknown, Other, Topical.
By species: Dog (15,087 reports), Unknown (222 reports), Human (46 reports). By breed: Retriever - Labrador (1,099), Shih Tzu (803), Chihuahua (718).
Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (2,678), Vomiting (2,547), Elevated serum alkaline phosphatase (SAP) (2,413), Hyperkalaemia (2,292). Outcome, 14,954 coded reports: Outcome Unknown leads at 59.7%.
Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.